MeetKai Brasil Named Final Winner of SERPRO's Sovereign AI Government Contract
SERPRO, the largest publicly-owned IT company in the world, acting as a central technology and data provider for the Brazilian federal government, has chosen MeetKai Brasil to lead the country's sovereign AI program.
BRASÍLIA,
SERPRO,
SERPRO's Sovereign AI initiative is designed to build a national AI platform powered by large language models trained in Portuguese and operated on Brazilian infrastructure. The platform is expected to support public-sector modernization, automate administrative processes, improve decision-making, and reduce reliance on foreign technology.
"At MeetKai, we believe artificial intelligence delivers the greatest value when it is secure, multilingual, locally governed, and purpose-built to solve public challenges at scale," said
"SERPRO's rigorous and transparent selection process set a high standard for public-sector AI," said Peter John Alexander, President & Chief Business Officer of MeetKai. "MeetKai and MeetKai Brasil are excited to work with more companies across
About MeetKai
Founded in Los Angeles in 2018, MeetKai is a Sovereign AI company specializing in post-training optimization, local-language reasoning models, and national AI platforms. Its flagship MK-A1 Platform enables governments, enterprises, and institutions to build and operate fully sovereign AI ecosystems, ensuring data control, localization, and long-term value creation. MeetKai is building the future of Sovereign AI for countries, enterprises, and institutions worldwide.
Learn more at www.meetkai.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/meetkai-brasil-named-final-winner-of-serpros-sovereign-ai-government-contract-302813433.html
SOURCE MeetKai
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
- Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
- Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share